Literature DB >> 18195720

Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells.

Wouter H P Driessen1, Nobutaka Fujii, Hirokazu Tamamura, Sean M Sullivan.   

Abstract

A peptide analog, 4-fluorobenzoyl-RR-(L-3-(2-naphthyl)alanine)-CYEK-(L-citrulline)-PYR-(L-citrulline)-CR, covalently linked to a phospholipid, was used for targeting a lipid-based gene delivery vehicle to CXCR4(+)-cells. Characterization of transfection activity was done in vitro using a transformed rat glioma cell line (RG2) that expresses CXCR4. The substitution of the targeting lipid at increasing mole percentages in the place of helper lipids yielded a progressive increase in reporter gene expression, reaching a maximum of 2.5 times the control value at 20 mol% of ligand. The substitution of helper lipids with cysteine-derivatized phospholipid analog or phosphatidylethanolamine resulted in a progressive decrease in transfection activity, with complete inactivation of the complex occurring at 20 mol%. A DNA dose-response with 10 mol% of lipopeptide reduced the effective DNA dose at least fivefold with regard to the number of transfected cells and >20-fold with regard to the amount of gene expression. Gene transfer to rat endothelial cells was studied in the context of an arterial organ culture. Mesenteric arteries were cannulated and maintained in culture for up to 4 days. CXCR4 cell-surface expression on endothelial cells was induced after overnight incubation with vascular endothelial growth factor (VEGF). Gene transfer studies showed that only the peptide-targeted lipoplexes transfected the endothelium, and only after CXCR4 had been induced with VEGF. These results demonstrate that non-viral transfection complexes can be targeted to cells expressing CXCR4, and that gene transfer is dependent upon cell surface receptor expression levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195720     DOI: 10.1038/sj.mt.6300388

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

1.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.

Authors:  Yan Wang; Ying Xie; David Oupický
Journal:  Curr Pharmacol Rep       Date:  2016-01-04

2.  In vivo anti-tumor effect of expressing p14ARF-TAT using a FGF2-targeted cationic lipid vector.

Authors:  Guoqin Niu; Wouter H P Driessen; Sean M Sullivan; Jeffrey A Hughes
Journal:  Pharm Res       Date:  2011-01-19       Impact factor: 4.200

3.  A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.

Authors:  Q Shi; A T Nguyen; Y Angell; D Deng; C-R Na; K Burgess; D D Roberts; F C Brunicardi; N S Templeton
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

Review 4.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

5.  Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion.

Authors:  Jing Li; Yu Zhu; Stuart T Hazeldine; Chunying Li; David Oupický
Journal:  Angew Chem Int Ed Engl       Date:  2012-07-31       Impact factor: 15.336

6.  Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9.

Authors:  Jianhong Zuo; Meiling Wen; Sai Li; Xiu Lv; Lei Wang; Xiaohong Ai; Mingsheng Lei
Journal:  Oncol Lett       Date:  2017-10-11       Impact factor: 2.967

7.  Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes.

Authors:  Anna A Egorova; Sofia V Shtykalova; Marianna A Maretina; Dmitry I Sokolov; Sergei A Selkov; Vladislav S Baranov; Anton V Kiselev
Journal:  Pharmaceutics       Date:  2019-06-06       Impact factor: 6.321

Review 8.  Ligand-directed cancer gene therapy to angiogenic vasculature.

Authors:  Wouter H P Driessen; Michael G Ozawa; Wadih Arap; Renata Pasqualini
Journal:  Adv Genet       Date:  2009       Impact factor: 1.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.